CytoMed Therapeutics Limited (GDTC)

CytoMed Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for GDTC stock has a target of 5.00, which predicts an increase of 133.64% from the current stock price of 2.14.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$5.00	$5.00	$5.00	$5.00
Change	+133.64%	+133.64%	+133.64%	+133.64%

* Price targets were last updated on Dec 4, 2023.

Analyst Ratings

According to 1 stock analyst, the rating for GDTC is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '24	Mar '24	Apr '24
Strong Buy	0	0	0
Buy	1	1	1
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Bruce Jackson Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+133.64%	Dec 4, 2023
Bruce Jackson Benchmark	Benchmark	Buy Initiates $5	Buy	Initiates	$5	+133.64%	Jul 21, 2023

More Analyst Ratings

Financial Forecast

• Revenue This Year:
  530.40K

Year	2020	2021	2022	2023	2024	2025
Revenue	-	-	-	-	530.40K	530.40K
Revenue Growth	-	-	-	-	-	-
EPS	-0.33	-0.30	-0.40	-0.39	-0.20	-0.20
EPS Growth	-	-	-	-	-	-
No. Analysts	-	-	-	-	3	3

Financial currency is SGD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2024	2025
High	546,000	546,000
Avg	530,400	530,400
Low	509,600	509,600

Revenue Growth

Revenue Growth	2024	2025
High	-	2.9%
Avg	-	-
Low	-	-3.9%

EPS Forecast

EPS	2024	2025
High	-0.21	-0.21
Avg	-0.20	-0.20
Low	-0.20	-0.20

EPS Growth

EPS Growth	2024	2025
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.